This company has been marked as potentially delisted and may not be actively trading. XTL Biopharmaceuticals (XTLB) Short Interest Ratio & Short Volume Add Compare Share Share Short Interest Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrendsBuy This Stock XTL Biopharmaceuticals Short Interest DataXTL Biopharmaceuticals (XTLB) has a short interest of 25,100 shares. This marks a 796.43% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.7, indicating that it would take 0.7 days of the average trading volume of 28,555 shares to cover all short positions.Current Short Interest25,100 sharesPrevious Short Interest2,800 sharesChange Vs. Previous Month+796.43%Dollar Volume Sold Short$39.91 thousandShort Interest Ratio0.7 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares5,450,000 sharesPercentage of Shares Shorted0.46%Today's Trading Volume0 sharesAverage Trading Volume28,555 sharesToday's Volume Vs. Average0% Short Selling XTL Biopharmaceuticals? Sign up to receive the latest short interest report for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartXTLB Short Interest Over TimeXTLB Days to Cover Over TimeXTLB Percentage of Float Shorted Over Time XTL Biopharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202525,100 shares $39.91 thousand +796.4%N/A0.7 $1.59 6/30/20252,800 shares $3.16 thousand -92.8%0.1%0.2 $1.13 6/15/202538,900 shares $49.79 thousand +6.3%1.0%1.4 $1.28 5/31/202536,600 shares $43.92 thousand -4.7%0.9%4.6 $1.20 5/15/202538,400 shares $43.01 thousand -20.0%1.0%4.5 $1.12 4/30/202548,000 shares $68.16 thousand -11.3%N/A6.1 $1.42 4/15/202554,100 shares $63.30 thousand -1.1%1.4%10.4 $1.17 3/31/202554,700 shares $65.91 thousand -2.8%1.4%9.4 $1.21 3/15/202556,300 shares $69.25 thousand -17.3%1.5%6.7 $1.23 2/28/202568,100 shares $92.28 thousand -16.0%1.8%6.5 $1.36 Get the Latest News and Ratings for XTLB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/15/202581,100 shares $133.09 thousand -4.1%2.1%8.1 $1.64 1/31/202584,600 shares $138.32 thousand -7.1%N/A7.8 $1.64 1/15/202591,100 shares $169.45 thousand -1.1%N/A2.1 $1.86 12/31/202492,100 shares $171.31 thousand +30.1%N/A2.1 $1.86 12/15/202470,800 shares $127.44 thousand -5.6%N/A1.7 $1.80 11/30/202475,000 shares $141 thousand -0.3%N/A1.9 $1.88 11/15/202475,200 shares $138.37 thousand -64.8%N/A1.9 $1.84 10/31/2024213,400 shares $475.88 thousand +2,381.4%N/A5.4 $2.23 10/15/20248,600 shares $19.09 thousand -41.5%N/A1 $2.22 9/30/202414,700 shares $35.57 thousand +51.6%N/A1.4 $2.42 9/15/20249,700 shares $25.50 thousand +1.0%N/A0.9 $2.63 8/31/20249,600 shares $26.78 thousand -7.7%N/A0.6 $2.79 8/15/202410,400 shares $29.02 thousand +103.9%N/A0.6 $2.79 7/31/20245,100 shares $14.69 thousand -64.3%N/A0.3 $2.88 7/15/202414,300 shares $35.61 thousand -19.2%N/A0.8 $2.49 6/30/202417,700 shares $43.01 thousand +78.8%N/A0.8 $2.43 6/15/20249,900 shares $20.20 thousand -55.0%N/A0 $2.04 5/31/202422,000 shares $57.20 thousand -13.4%N/A0 $2.60 5/15/202425,400 shares $69.60 thousand +13.4%N/A0 $2.74 4/30/202422,400 shares $57.79 thousand -62.8%N/A0 $2.58 4/15/202460,200 shares $161.34 thousand -86.2%N/A0.1 $2.68 3/31/2024437,200 shares $1.23 million +21,760.0%N/A0.6 $2.81 3/15/20242,000 shares $1.76 thousand +11.1%N/A0 $0.88 2/29/20241,800 shares $1.53 thousand -37.9%N/A0.6 $0.85 2/15/20242,900 shares $2.61 thousand -42.0%N/A0.9 $0.90 1/31/20245,000 shares $4.38 thousand -27.5%N/A1.4 $0.88 1/15/20246,900 shares $6.01 thousand +1.5%N/A1.9 $0.87 12/31/20236,800 shares $6.87 thousand -32.7%N/A1.7 $1.01 12/15/202310,100 shares $9.97 thousand -15.8%N/A3.9 $0.99 11/30/202312,000 shares $12.36 thousand +36.4%N/A5.7 $1.03Elon’s BIGGEST warning yet? (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.Click here to see why Tesla's about to prove everyone wrong... again. 11/15/20238,800 shares $6.86 thousand -24.8%N/A2.7 $0.78 10/31/202311,700 shares $10.15 thousand +62.5%N/A3.2 $0.87 10/15/20237,200 shares $6.48 thousand -22.6%N/A1.3 $0.90 9/30/20239,300 shares $8.35 thousand -3.1%N/A1.7 $0.90 9/15/20239,600 shares $9.31 thousand +29.7%N/A1.5 $0.97 8/31/20237,400 shares $7.77 thousand +236.4%N/A0.5 $1.05 8/15/20232,200 shares $2.09 thousand +29.4%N/A0.2 $0.95 7/31/20231,700 shares $1.39 thousand -19.1%N/A0.1 $0.82 7/15/20232,100 shares $2.14 thousand -16.0%N/A0.1 $1.02 6/30/20232,500 shares $2.38 thousand -28.6%N/A0.2 $0.95 6/15/20233,500 shares $4.62 thousand -25.5%N/A0.2 $1.32 5/31/20234,700 shares $5.73 thousand +27.0%N/A0.6 $1.22 5/15/20233,700 shares $4.48 thousand +23.3%N/A0.5 $1.21 4/30/20233,000 shares $3.36 thousand -55.2%N/A0.5 $1.12 4/15/20236,700 shares $8.24 thousand -23.0%N/A1.7 $1.23 3/31/20238,700 shares $11.05 thousand +117.5%N/A4.1 $1.27 3/15/20234,000 shares $4.92 thousand +2.6%N/A1.6 $1.23 2/28/20233,900 shares $5.46 thousand -7.1%N/A1.3 $1.40 2/15/20234,200 shares $5.59 thousand -16.0%N/A1.5 $1.33 1/31/20235,000 shares $5.85 thousand -12.3%N/A1.4 $1.17 1/15/20235,700 shares $7.87 thousand +2,750.0%N/A1.7 $1.38 12/30/2022200 shares $242.00 -95.7%N/A0.1 $1.21 12/15/20224,700 shares $5.69 thousand -6.0%N/A1 $1.21 11/30/20225,000 shares $6.65 thousand +6.4%N/A1.2 $1.33 11/15/20224,700 shares $6.67 thousand +261.5%N/A1 $1.42 10/31/20221,300 shares $1.68 thousand -40.9%N/A0.3 $1.29 10/15/20222,200 shares $2.65 thousand +83.3%N/A0.3 $1.21 9/30/20221,200 shares $1.33 thousand -77.4%N/A0.2 $1.11 9/15/20225,300 shares $7.16 thousand -22.1%N/A0.9 $1.35 8/31/20226,800 shares $10.06 thousand +4.6%N/A1.2 $1.48 8/15/20226,500 shares $11.12 thousand +8.3%N/A1.2 $1.71 7/31/20226,000 shares $9.78 thousand -25.9%N/A1.1 $1.63 7/15/20228,100 shares $12.23 thousand +42.1%N/A2.9 $1.51 6/30/20225,700 shares $8.66 thousand +11.8%N/A1.7 $1.52 6/15/20225,100 shares $7.85 thousand -13.6%N/A1.5 $1.54 5/31/20225,900 shares $10.71 thousand -37.2%N/A0.9 $1.82 5/15/20229,400 shares $15.89 thousand +20.5%N/A1.5 $1.69 4/30/20227,800 shares $17.16 thousand +9.9%N/A1.4 $2.20 4/15/20227,100 shares $16.69 thousand +16.4%N/A1.2 $2.35 3/31/20226,100 shares $14.46 thousand +96.8%N/A0.9 $2.37 3/15/20223,100 shares $6.62 thousand +121.4%N/A0.3 $2.13 2/28/20221,400 shares $3.33 thousand -17.7%N/A0.1 $2.38 2/15/20221,700 shares $4.11 thousand No ChangeN/A0.1 $2.42 1/31/20221,700 shares $4.28 thousand -56.4%N/A0.1 $2.52 1/15/20223,900 shares $11.35 thousand -17.0%N/A0.1 $2.91 12/31/20214,700 shares $13.02 thousand +147.4%N/A0.2 $2.77 12/15/20211,900 shares $5.57 thousand -64.2%N/A0.1 $2.93 11/30/20215,300 shares $16.96 thousand +960.0%N/A0.2 $3.20 11/15/2021500 shares $1.79 thousand -58.3%N/A0 $3.58 10/29/20211,200 shares $4.58 thousand -60.0%N/A0 $3.82Elon’s BIGGEST warning yet? (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.Click here to see why Tesla's about to prove everyone wrong... again. 10/15/20213,000 shares $11.79 thousand -85.2%N/A0 $3.93 9/30/202120,200 shares $88.48 thousand +1.0%N/A0.1 $4.38 9/15/202120,000 shares $82.80 thousand -68.7%N/A0.1 $4.14 8/31/202163,900 shares $316.31 thousand +75.6%N/A0.4 $4.95 8/13/202136,400 shares $129.22 thousand -15.7%N/A0.3 $3.55 7/30/202143,200 shares $151.20 thousand +37.6%N/A0.5 $3.50 7/15/202131,400 shares $108.96 thousand -35.3%N/A0.4 $3.47 6/30/202148,500 shares $193.52 thousand +40.2%N/A3.4 $3.99 6/15/202134,600 shares $119.37 thousand -2.8%N/A2.1 $3.45 5/28/202135,600 shares $125.68 thousand +14.8%N/A1.5 $3.53 5/14/202131,000 shares $103.23 thousand -19.7%N/A0.1 $3.33 4/30/202138,600 shares $137.42 thousand -5.6%N/A0.1 $3.56 4/15/202140,900 shares $132.52 thousand -1.2%N/A0.2 $3.24 3/31/202141,400 shares $136.21 thousand -19.8%N/A0.2 $3.29 3/15/202151,600 shares $174.92 thousand +719.1%N/A0.2 $3.39 2/26/20216,300 shares $19.15 thousand -77.7%N/A0 $3.04 2/12/202128,200 shares $106.60 thousand +464.0%N/A1 $3.78 1/29/20215,000 shares $16.10 thousand -76.5%N/A0.2 $3.22 1/15/202121,300 shares $84.14 thousand +88.5%N/A0.8 $3.95 12/31/202011,300 shares $35.76 thousand -76.6%N/A0.4 $3.17 12/15/202048,200 shares $126.77 thousand +518.0%N/A2.5 $2.63 11/30/20207,800 shares $19.57 thousand -34.5%N/A0.5 $2.51 10/30/20206,900 shares $15.32 thousand -46.1%N/A0.4 $2.22 10/15/202012,800 shares $27.90 thousand -14.1%N/A0.7 $2.18 9/30/202014,900 shares $28.31 thousand +156.9%N/A0.9 $1.90 9/15/20205,800 shares $12.59 thousand +65.7%N/A0.3 $2.17 8/31/20203,500 shares $5.95 thousand +483.3%N/A0.1 $1.70 8/14/2020600 shares $1.03 thousand -45.5%N/A0 $1.72 XTLB Short Interest - Frequently Asked Questions What is XTL Biopharmaceuticals' current short interest? Short interest is the volume of XTL Biopharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of July 15th, investors have sold 25,100 shares of XTLB short. Learn More on XTL Biopharmaceuticals' current short interest. What is a good short interest ratio for XTL Biopharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. XTLB shares currently have a short interest ratio of 1.0. Learn More on XTL Biopharmaceuticals's short interest ratio. Is XTL Biopharmaceuticals' short interest increasing or decreasing? XTL Biopharmaceuticals saw a increase in short interest in July. As of July 15th, there was short interest totaling 25,100 shares, an increase of 796.4% from the previous total of 2,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does XTL Biopharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to XTL Biopharmaceuticals: Karyopharm Therapeutics Inc. (26.01%), Precision Optics Corp. (1.12%), PolyPid Ltd. (0.98%), Akari Therapeutics PLC (0.13%), Xilio Therapeutics, Inc. (18.63%), Clearside Biomedical, Inc. (0.21%), MEDIROM Healthcare Technologies Inc. (0.12%), Rockwell Medical, Inc. (0.53%), Rani Therapeutics Holdings, Inc. (29.83%), Dyadic International Inc. (0.52%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short XTL Biopharmaceuticals stock? Short selling XTLB is an investing strategy that aims to generate trading profit from XTL Biopharmaceuticals as its price is falling. XTLB shares are trading up $0.35 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against XTL Biopharmaceuticals? A short squeeze for XTL Biopharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of XTLB, which in turn drives the price of the stock up even further. How often is XTL Biopharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XTLB, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies Karyopharm Therapeutics Short Squeeze Precision Optics Short Squeeze PolyPid Short Squeeze Akari Therapeutics Short Squeeze Xilio Therapeutics Short Squeeze Clearside Biomedical Short Squeeze MEDIROM Healthcare Technologies Short Squeeze Rockwell Medical Short Squeeze Rani Therapeutics Short Squeeze Dyadic International Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:XTLB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
